Skip to main content
David Fisher, MD, Plastic Surgery, Charlotte, NC, Atrium Health University City

DavidCFisherMDFACS

Plastic Surgery Charlotte, NC

Head & Neck, Pediatric Craniofacial Plastic Surgery, Pediatric Plastic Surgery, Plastic & Reconstructive Microsurgery

Physician

Dr. Fisher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fisher's full profile

Already have an account?

Summary

  • Dr. David Fisher is a plastic surgeon in Charlotte, NC and is affiliated with multiple hospitals in the area, including Carolinas Medical Center, Atrium Health University City, and Carolinas Medical Center.

Education & Training

  • The Royal Children’s Hospital, Melbourne
    The Royal Children’s Hospital, Melbourne Fellow, Pediatric, Cleft & Craniomaxillofacial Surgery , 2014 - 2015
  • Auckland City Hospital
    Auckland City HospitalFellow, Head and Neck Surgical Oncology and Microsurgery , 2010 - 2011
  • Wake Forest University School of Medicine
    Wake Forest University School of MedicineResidency, Plastic Surgery - Integrated, 2004 - 2010
  • Wake Forest School of Medicine of Wake Forest Baptist Medical Center
    Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2004

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2004 - 2025
  • American Board of Plastic Surgery Plastic Surgery

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
    David C. Fisher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
    David C. Fisher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Hospital Affiliations